• Taux USA 10Y +1,82 %
  • Taux FR 10Y +-0,05 %
Matières premières
  • Pétrole WTI56,55 $
  • Cours Or 1486,05 $
Forex
  • Bitcoin 9322,67 $
  • Eur/Usd 1,11
Chiffres clés - Inflation
  • Europe +1.70 % / an
  • France +1.20 % / an
Chiffres clés
  • PIB Europe +1.50 % / an
  • PIB France +0.90 % / an
Accueil » Bourse de Paris » Communiqués
line
line

Ablynx et le national research council canada (conseil national de la recherche du canada) signent un accord de collaboration portant sur le developpement de nanocorps (nanobodiese) dans les troubles du systeme nerveux central

Catégorie : , Canada

Source : Hugin Posté dans la rubrique le 26/05/2005 à  11:54


 canada

Presse économique / Biotechnologie

GAND, Belgique -- (BUSINESS WIRE) -- May 26, 2005 -- Ablynx, laboratoire pionnier dans la découverte et le développement des Nanobodies™ (« nanocorps »), une nouvelle classe de protéines thérapeutiques dérivées de fragments d'anticorps simple domaine, a annoncé ce jour la conclusion d'un accord de collaboration portant sur la recherche, le développement et la concession en licence des Nanobodies™ avec l'Institut des Sciences biologiques (IBS, Institute for Biological Sciences) du Conseil national de la recherche du Canada (National Research Council Canada), établi à Ottawa. Cette collaboration contribuera de manière importante aux efforts de découverte mis en œuvre par Ablynx dans le domaine des maladies neurodégénératives.

(BW)(ABLYNX) Ablynx and the National Research Council Canada Sign Collaborative Deal to Develop Nanobodies for CNS Disorders

Business Editors/Biotech Writers

GHENT, Belgium--(BUSINESS WIRE)--May 26, 2005--Ablynx, a pioneer in the discovery and development of Nanobodies(TM), a novel class of therapeutic proteins derived from single-domain antibody fragments, today announced that it has signed a collaborative research, development and license agreement with the Ottawa-based National Research Council of Canada (NRC) Institute for Biological Sciences (IBS).This collaboration will make an important contribution to Ablynx's discovery efforts in the area of neurodegenerative diseases. NRC researchers have identified a class of Nanobodies(TM) that, unlike many other drugs or conventional antibodies, cross the blood-brain barrier (BBB) in a selective and efficient manner.

Ablynx will now collaborate on these BBB-crossing Nanobodies(TM) with NRC, to develop novel diagnostics and therapeutics for diseases of the Central Nervous System (CNS).

In the first instance, Ablynx and the NRC will evaluate the potential of these Nanobodies(TM) for applications in Alzheimer's disease.

Dr Mark Vaeck, CEO of Ablynx, commented:

"The fact that NRC has identified Nanobodies(TM) that can, uniquely, pass the blood-brain barrier underlines the power and versatility of Ablynx's platform.

We have already demonstrated the therapeutic potential of Nanobodies(TM) in several important disease areas like oncology, inflammation and thrombosis.

This agreement with the NRC is the latest example of Ablynx's strategy to partner with leading experts worldwide to develop Nanobodies(TM) for important therapeutic applications."

Commenting on the deal, Dr Gabrielle Adams, Director General of the NRC-IBS, said: "Neurodegenerative diseases, such as Alzheimer's, have a high unmet medical need, both for better diagnostics and effective therapies.

The unique properties of the BBB-crossing Nanobodies(TM) makes them ideal for use as components in novel diagnostic imaging products and as a means to efficiently transport therapeutic drugs into the brain.

We are delighted to have partnered with Ablynx for the commercial development of our discoveries."

Nanobodies(TM) are a novel class of therapeutic proteins that combine the beneficial features of conventional antibodies with desirable properties of small molecule drugs.

Nanobodies(TM) have the affinity and selectivity of conventional antibodies yet are only a fraction of their size.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(TM) for a range of human diseases.

Because of their small size, unique structure and unparalleled stability, Nanobodies(TM) combine the advantages of conventional antibodies with key features of small molecule drugs.

Ablynx is currently developing Nanobodies(TM) for the treatment of autoimmune diseases, thrombosis, cancer and neurodegenerative conditions. Ablynx holds the dominant patent position in the field of Nanobodies(TM) and has exclusive rights to more than fifty granted patents and pending patent applications, including an exclusive license to the patents covering the basic structure, composition, preparation and uses of Nanobodies(TM) (the 'Hamers patents')

.

All products, including therapeutics, that contain Nanobodies(TM) are covered by these patents.

Ablynx has raised over EUR 33 million (over US$40 million) from a strong investor consortium including Abingworth Management (UK), Alta Partners (USA), Gilde Investment Management (The Netherlands), GIMV (Belgium) and Sofinnova Partners (France). For further information please visit the website at www.ablynx.com.

About the National Research Council Canada (NRC)

Recognized globally for research and innovation, NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology.

It has earned a world-wide reputation for its research expertise, its track record of successful partnerships, its scientific standards and high-quality scientific and technical publishing.

NRC operates world-class research facilities, and provides information, technology and innovation support networks for users in Canada and abroad. One of NRC's Ottawa research facilities, NRC-IBS conducts innovative research in the two principal areas of neurobiology and immunochemistry.

Research programs are carried out with partners in industry, universities, hospitals, and other R&D organizations.

The institute also has a strong track record for transferring technology and knowledge to multinational, as well as small -and medium- sized Canadian firms. For further information please visit the website at www.nrc-cnrc.gc.ca.

CONTACT:

Northbank Communications

Sue Charles, +44 (0) 20 7886 8152 s.charles@northbankcommunications.com

or

Douglas Pretsell, +44 (0) 20 7886 8158 d.pretsell@northbankcommunications.com

or

Ablynx

Mark Vaeck, +32 (0) 9 261 06 20 mark.vaeck@ablynx.com

or

National Research Council Canada

Alex Myers, +1 (613) 998-7352 media@nrc-cnrc.gc.ca




share
pin it


A VOIR AUSSI
Commentaires

0 commentaires
Ajouter votre commentaire !
Pour réagir à cette info : Connectez-vous à votre espace membre
Ajouter le smiley Sourire  Ajouter le smiley Rigole  Ajouter le smiley Tire la langue  Ajouter le smiley Clin d'oeil  Ajouter le smiley En colère !  Ajouter le smiley Embarrassé  Ajouter le smiley Choqué  Ajouter le smiley Star  Ajouter le smiley Triste
Vous devez être membre de leguideboursier.com pour ajouter votre commentaire. Cliquez-ici pour devenir membre !

Conditions d'utilisation
Les commentaires sont envoyés par les internautes et ne sont pas rédigés par notre rédaction.
Notre rédaction se réserve le droit de supprimer les commentaires ne respectant pas notre charte éditoriale.
Il est interdit d'écrire des commentaires contraires aux lois françaises.
Le commentaire une fois diffusé ne peut etre supprimé ou modifié qu'en envoyant un email
Mentions légales

Ce contenu est diffusé par Hugin, il n`a qu`une portée informative et pédagogique.
Les informations et données financières ainsi que les analyses diffusées par Hugin n`ont aucune valeur contractuelle et ne constituent en aucun cas une aide à la décision, une offre de vente ou une sollicitation d`achat de valeurs mobilières ou d`instruments financiers.
La responsabilité de LeGuideBoursier.com et/ou de ses dirigeants et salariés ne peut être retenue directement ou indirectement suite à l`utilisation des informations et analyses par les lecteurs et sur la pertinence des informations diffusées.
Il est recommandé à toute personne non avertie de consulter un conseiller professionnel avant tout investissement, car le trading peut vous exposer à des pertes supérieures aux dépôts chez votre broker.
Tout investisseur doit se faire son propre jugement avant d`investir dans un produit financier afin qu`il soit adapté à sa situation financière, fiscale et légale.
Contenu proposé par Le guide boursier : D'autres articles qui pourraient vous intérresser
-